Management of pulmonary toxicity associated with immune checkpoint inhibitors
作者: Myriam DelaunayGrégoire PrévotSamia CollotLaurent GuilleminaultAlain DidierJulien Mazières
作者单位: 1Respiratory Disease Dept, Larrey Hospital, University Hospital of Toulouse, Paul Sabatier University, Toulouse, France
2Radiology Dept, Rangueil Hospital, University Hospital of Toulouse, Toulouse, France
刊名: European Respiratory Review, 2019, Vol.28 (154)
来源数据库: European Respiratory Society
DOI: 10.1183/16000617.0012-2019
原始语种摘要: Immunotherapy has become a standard of care in oncology, following the recent approvals of cytotoxic T-lymphocyte-associated protein-4 and programmed cell death-1 inhibitors in lung cancer, melanoma, renal cell carcinoma, Hodgkin's lymphoma, bladder, head and neck cancers. Besides their efficacy, these agents also generate specific immune-related adverse events. Due to the increasing prescription of immune-checkpoint inhibitors, the incidence of immune toxicity will continue to rise. The awareness of immune-related adverse events is key to ensuring both diagnosis and management of the possible serious adverse events. Although severe immune-related adverse events remain rare, they can lead to discontinued treatment or to death if they are not forecasted and managed properly. Even if lung...
全文获取路径: ERS  (合作)
分享到:

×
关键词翻译
关键词翻译
  • immune 免疫的
  • toxicity 毒性
  • associated 相关的
  • checkpoint 检查地点
  • pulmonary 肺的
  • remains 残渣
  • events 定时
  • lymphocyte 淋巴细胞
  • cytotoxic 细胞毒素的
  • adverse 逆的